U.S. markets open in 4 hours 53 minutes
  • S&P Futures

    4,207.50
    -15.50 (-0.37%)
     
  • Dow Futures

    33,895.00
    -122.00 (-0.36%)
     
  • Nasdaq Futures

    13,905.50
    -75.75 (-0.54%)
     
  • Russell 2000 Futures

    2,299.90
    -10.20 (-0.44%)
     
  • Crude Oil

    71.76
    -0.39 (-0.54%)
     
  • Gold

    1,807.00
    -54.40 (-2.92%)
     
  • Silver

    26.88
    -0.93 (-3.35%)
     
  • EUR/USD

    1.1956
    -0.0044 (-0.37%)
     
  • 10-Yr Bond

    1.5690
    0.0000 (0.00%)
     
  • Vix

    18.79
    +1.77 (+10.40%)
     
  • GBP/USD

    1.3987
    0.0000 (-0.00%)
     
  • USD/JPY

    110.6200
    +0.0070 (+0.01%)
     
  • BTC-USD

    39,345.29
    -683.71 (-1.71%)
     
  • CMC Crypto 200

    977.56
    -14.91 (-1.50%)
     
  • FTSE 100

    7,155.55
    -29.40 (-0.41%)
     
  • Nikkei 225

    29,018.33
    -272.68 (-0.93%)
     

DexCom, Inc. (NASDAQ:DXCM) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?

  • Oops!
    Something went wrong.
    Please try again later.
·3 min read
  • Oops!
    Something went wrong.
    Please try again later.

DexCom (NASDAQ:DXCM) has had a rough three months with its share price down 21%. However, a closer look at its sound financials might cause you to think again. Given that fundamentals usually drive long-term market outcomes, the company is worth looking at. Specifically, we decided to study DexCom's ROE in this article.

Return on equity or ROE is an important factor to be considered by a shareholder because it tells them how effectively their capital is being reinvested. In other words, it is a profitability ratio which measures the rate of return on the capital provided by the company's shareholders.

See our latest analysis for DexCom

How Do You Calculate Return On Equity?

Return on equity can be calculated by using the formula:

Return on Equity = Net Profit (from continuing operations) ÷ Shareholders' Equity

So, based on the above formula, the ROE for DexCom is:

27% = US$514m ÷ US$1.9b (Based on the trailing twelve months to March 2021).

The 'return' is the amount earned after tax over the last twelve months. One way to conceptualize this is that for each $1 of shareholders' capital it has, the company made $0.27 in profit.

What Is The Relationship Between ROE And Earnings Growth?

We have already established that ROE serves as an efficient profit-generating gauge for a company's future earnings. We now need to evaluate how much profit the company reinvests or "retains" for future growth which then gives us an idea about the growth potential of the company. Assuming all else is equal, companies that have both a higher return on equity and higher profit retention are usually the ones that have a higher growth rate when compared to companies that don't have the same features.

A Side By Side comparison of DexCom's Earnings Growth And 27% ROE

Firstly, we acknowledge that DexCom has a significantly high ROE. Secondly, even when compared to the industry average of 10% the company's ROE is quite impressive. Under the circumstances, DexCom's considerable five year net income growth of 61% was to be expected.

As a next step, we compared DexCom's net income growth with the industry, and pleasingly, we found that the growth seen by the company is higher than the average industry growth of 14%.

past-earnings-growth
past-earnings-growth

The basis for attaching value to a company is, to a great extent, tied to its earnings growth. The investor should try to establish if the expected growth or decline in earnings, whichever the case may be, is priced in. By doing so, they will have an idea if the stock is headed into clear blue waters or if swampy waters await. One good indicator of expected earnings growth is the P/E ratio which determines the price the market is willing to pay for a stock based on its earnings prospects. So, you may want to check if DexCom is trading on a high P/E or a low P/E, relative to its industry.

Is DexCom Making Efficient Use Of Its Profits?

Conclusion

In total, we are pretty happy with DexCom's performance. In particular, it's great to see that the company is investing heavily into its business and along with a high rate of return, that has resulted in a sizeable growth in its earnings. Having said that, the company's earnings growth is expected to slow down, as forecasted in the current analyst estimates. To know more about the latest analysts predictions for the company, check out this visualization of analyst forecasts for the company.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.